Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1989 Dec;8(12):1102-10.
doi: 10.1007/BF01975177.

Clinical utility of new quinolones in treatment of osteomyelitis and lower respiratory tract infections

Affiliations
Review

Clinical utility of new quinolones in treatment of osteomyelitis and lower respiratory tract infections

A S Bayer. Eur J Clin Microbiol Infect Dis. 1989 Dec.

Abstract

In the eight major clinical studies published on use of oral quinolones in therapy of contiguous osteomyelitis, clinical and microbiologic cure/improvement rates were 75% and 73%, respectively, when drug therapy was combined with appropriate surgical debridement. This included many cases of polymicrobial osteomyelitis, as well as infection caused by recalcitrant pathogens such as Pseudomonas aeruginosa. In contrast, the response of staphylococcal osteomyelitis to oral quinolones, especially in cases caused by methicillin-resistant strains, appeared suboptimal. Quinolones appear to have a limited role in the treatment of community-acquired pneumonia, since other established antibiotic regimens have been proven effective in such situations. Quinolones may play an important role in the treatment of nosocomially acquired aerobic gram-negative bacillary pneumonia, either as primary parenteral therapy or as transitional oral therapy when affected patients become outpatients. In cystic fibrosis-associated acute exacerbations of chronic pseudomonal pneumonitis, the outcome of oral ciprofloxacin therapy was very satisfactory in the six major studies reported (approximately 85% improvement rates). In three comparative studies oral quinolone treatment of such pulmonary exacerbations resulted in clinical response rates equivalent to those for aminoglycoside plus beta-lactam therapy given intravenously. Quinolone-resistant Pseudomonas aeruginosa strains were commonly isolated from sputum during treatment; however, such patients continued to respond clinically to quinolone treatment, and sputum became rapidly repopulated with quinolone-susceptible Pseudomonas aeruginosa strains after discontinuation of therapy.

PubMed Disclaimer

References

    1. J Antimicrob Chemother. 1984 Mar;13(3):237-44 - PubMed
    1. Antimicrob Agents Chemother. 1983 Aug;24(2):302-4 - PubMed
    1. Medicine (Baltimore). 1974 May;53(3):197-208 - PubMed
    1. Antimicrob Agents Chemother. 1986 Jun;29(6):1088-9 - PubMed
    1. Antimicrob Agents Chemother. 1986 Nov;30(5):743-8 - PubMed

MeSH terms

LinkOut - more resources